Amgen – Enviornment Prescribed drugs Declares R&D Management Transition
Information and analysis earlier than you hear about it on CNBC and others. Declare your 1-week free trial to StreetInsider Premium right here.
- Paul D. Streck, M.D., Appointed as Senior Vice President, Scientific Growth and Chief Medical Officer, Bringing Profitable Growth and Launch Expertise Throughout A number of Therapeutic Indications
SAN DIEGO–(BUSINESS WIRE)–
Enviornment Prescribed drugs, Inc. (Nasdaq: ARNA) as we speak introduced a transition of its R&D management and the appointment of Paul D. Streck, M.D., as Senior Vice President, Scientific Growth and Chief Medical Officer reporting to Amit Munshi, President and CEO. The transition follows the retirement and resignation of Chris Cabell, M.D., M.H.S., FACC, who served as the corporate’s Government Vice President, Head of Analysis and Growth, and Chief Medical Officer since June 2020. The change is efficient as of December 1, 2020 and Dr. Cabell will stay an advisor to the Firm.
Dr. Streck brings greater than 25 years of expertise in drug improvement, regulatory and medical affairs management throughout each giant and small publicly traded biopharmaceutical corporations, and a monitor report of success with six world regulatory launches, 5 IND’s and 9 business product launches.
“Having Dr. Streck’s deep executive experience as a physician in successful clinical development and medical affairs leadership roles puts Arena in a stronger position as we move toward completing late-stage clinical development into regulatory submission and pre-commercial planning. His proven global leadership roles across therapeutic indications provides for seamless integration for the Company’s current and future clinical and regulatory activities,” mentioned Amit D. Munshi, Enviornment’s President and Chief Government Officer.
“On behalf of Arena’s Board of Directors and management team, we would like to thank Chris for his ability to step into a critical role during an important time at our company. We wish him the best in his future endeavors.”
Most not too long ago, Dr. Streck served as Chief Medical Officer at Alder Biopharmaceuticals, Inc., a publicly traded biotechnology firm, acquired by Lundbeck in late 2019. On this function, Dr. Streck led medical improvement, medical operations, medical affairs, regulatory, and security/pharmacovigilance, and drove U.S. approval of Vyepti®, a biologic drugs for prevention of migraines. From 2017-2019, Dr. Streck was the Chief Medical Officer of Insmed, Inc., a publicly traded biotechnology firm. Earlier biopharmaceutical expertise consists of progressive roles at Amgen, Shire, and GSK. He additionally has 10 years of expertise in educational medical follow.
About Enviornment Prescribed drugs
ARENA Prescribed drugs is a staff with a singular goal – ship our necessary medicines to sufferers.
In a quickly altering world market, we work with a way of urgency on daily basis to know the wants of all our stakeholders, establish daring, generally disruptive, concepts to get our medicines to sufferers, and relentlessly execute till it is executed.
ARENA – Care Extra. Act In another way.
Sure statements on this press launch are forward-looking statements that contain numerous dangers and uncertainties. Such forward-looking statements embody, with out limitation, statements about Dr. Streck’s anticipated contributions, Enviornment’s place, drive, portfolio, prioritization, monetary place, staff, and constructing of the corporate. For such statements, Enviornment claims the safety of the Non-public Securities Litigation Reform Act of 1995. Precise occasions or outcomes may differ materially from Enviornment’s expectations. Elements that would trigger precise outcomes to vary materially from the forward-looking statements embody these disclosed in Enviornment’s filings with the Securities and Alternate Fee. These forward-looking statements signify Enviornment’s judgment as of the time of this launch. Enviornment disclaims any intent or obligation to replace these forward-looking statements, aside from as may be required beneath relevant legislation.
Enviornment Prescribed drugs, Inc.
Vice President, Investor Relations & Company Communications
Megan E. Knight
Enviornment Prescribed drugs, Inc.
Director, Investor Relations
Enviornment Media Contact:
Supply: Enviornment Prescribed drugs, Inc.